Search General Info
Search Education
Search Partnering Companies
Inflammatory Response Research, Inc.
11:30 AM - 11:45 AM (EDT), Wednesday, June 7, 2023 ・ Session Room 104B
![BIO International Convention](/sites/default/files/2021-09/_BIO_CONV_Logo-White.png)
IRR is a science-based drug development company focused on pharmaceutical products for the treatment of inflammatory disorders and conditions. Products under development incorporate the uniquely synergistic anti-inflammatory combination of levocetirizine (Xyzal®) and montelukast (Singulair®) at specific doses / administration.
In 2022, IRR received a significant Congressionally Directed Medical Research Program (CDMRP-DOD) award to facilitate development of a ‘First Response’, in-theater, combat injectable to mitigate inflammation following traumatic brain injury. The grant provides funding for formulation of the injectable as well as large animal study at PENN; replete with 9 biomarkers of inflammation and advanced neuroimaging. Upon advice from FDA consultants, the clinically discovered therapeutic has the potential to proceed directly to a Phase III clinical trial following completion of limited toxicology and pharmacokinetic analyses. Anticipated timeline to approval is 36 months.
In 2022, IRR received a significant Congressionally Directed Medical Research Program (CDMRP-DOD) award to facilitate development of a ‘First Response’, in-theater, combat injectable to mitigate inflammation following traumatic brain injury. The grant provides funding for formulation of the injectable as well as large animal study at PENN; replete with 9 biomarkers of inflammation and advanced neuroimaging. Upon advice from FDA consultants, the clinically discovered therapeutic has the potential to proceed directly to a Phase III clinical trial following completion of limited toxicology and pharmacokinetic analyses. Anticipated timeline to approval is 36 months.
![](https://778c1607566f28c5e8fd-e6db6de54823ad7fd298e0f6ff75b72a.ssl.cf1.rackcdn.com/BIO_4121_EOISBJNL_291_InflammatoryResponseResearchInc-FileId-329880.jpg)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2010
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
First Response Therapeutic to Treat Traumatic Brain Injury
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
two
Speaker
![](https://www.conferenceharvester.com/uploads/harvester/photos/EOISBJNL-Presenter-MayB.jpg)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved